The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia

Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease

“…As better acid suppression is seen in poor metabolizers of PPIs in regard to the CYP2C19 genotype, less acid supression is seen in extensive metabolizers (8). According to the polymorphism of CYP2C19, poor metabolizers in the West and Turkey account for approximately 1%-3% of the population, whereas this rate has been reported as approximately 20% in the far East (9,10). Optimally, the CYP2C19 genotype should be taken into consideration when comparing the effects of PPIs; however, most of the relevant studies have not provided data on this so far.…”